This research project focuses on the unwanted side effects of immunotherapy, which activates the immune system to fight cancer. These side effects, known as immune-mediated adverse events (irAEs), can interfere with or necessitate the discontinuation of life-saving cancer therapies. The aim of the project is to identify new molecular targets in various  tissue affected by irAEs (skin, intestine, liver, etc.) as well as patients’ blood. This will lead to more personalized and effective treatment strategies, enabling cancer patients to continue receiving immunotherapy without compromising its effectiveness. Additionally, it could prevent the interruption or termination of life-saving therapies due to these side effects.